China’s coronavirus vaccine gets special military drug approval

Clay Curtis
June 29, 2020

Beijing, June 28 (SocialNews.XYZ) A Covid-19 vaccine candidate developed by a Beijing unit of China National Biotec Group (CNBG) has shown positive results in early human trials, the company said on Sunday.

Measuring that with the first proven vaccine will "really help us understand for all the other vaccines in development, do they also have a chance?" said Oxford University lead researcher Sarah Gilbert.

Hong Kong-listed CanSino Biologics said in a filing to the stock exchange that data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease caused by the coronavirus.

No vaccine has been approved by any country for commercial use against the disease caused by coronavirus.

CanSino said on Monday that China's Central Military Commission had approved the use of the vaccine on 25 June, for one year. The vaccine prospect was formulated jointly by CanSino and a study institute at the Academy of Army Science. Trials started on 17 March.

Klopp urges Liverpool fans to celebrate title ‘in private’
Large crowds gathered at Pier Head in the city centre to celebrate Liverpool winning their first league title in 30 years. Fifteen people arrested on suspicion of violent disorder have been bailed while investigations continue.

"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the logistics support department", CanSino mentioned, referring to the Central Army Fee office which accepted the military use of the vaccine.

In an interview with Chemical and Engineering News, Wistar Institute scientist Hildegund C.J. Ertl, who works on adenoviral vector vaccines, said, "It is not great, but it is better than nothing". To stop it replicating, the virus is made inactive by removing certain genes.

The group appealed to the Secretary-General of the United Nations, Director-General of the World Health Organisation (WHO), as well as religious leaders, corporations and media companies to come together to ensure available COVID-19 vaccines. Once injected, these viral antigens are expressed in human cells that trigger the body's immune response.

CanSino added that it can not guarantee the vaccine - which had its phase one and two clinical trials done in China - will ultimately be commercialised. Thus, the AstraZeneca vaccine candidate, for example, is the outcome of a British research institution's collaboration with a British-Swedish pharma conglomerate, with clinical testing being done in Brazil.

None have yet been approved for commercial use against the coronavirus.

Other reports by

Discuss This Article